Zhongchao Inc. (ZCMD) - Form 20-F Summary
Business Context and Reporting Period
Company: Zhongchao Inc. (Cayman Islands holding company)
Reporting Period: Fiscal Year Ended December 31, 2024
Primary Operations: The Company operates through Variable Interest Entities (VIEs) in the People's Republic of China (PRC), primarily Zhongchao Medical Technology (Shanghai) Co., Ltd. It provides healthcare information, education, and training services to professionals (MDMOOC platform), patient management services for oncology and rare diseases (Zhongxin Health), and sales of patented drugs (Xinjiang Pharmaceutical).
Listing: Nasdaq Capital Market (Symbol: ZCMD). The Company is a non-accelerated filer and an emerging growth company.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 | 2023 | 2022 |
|---|---|---|---|
| Total Revenue | $15.86 million | $19.43 million | $14.15 million |
| Gross Profit | $8.91 million | $8.51 million | $6.36 million |
| Gross Margin | 56.2% | 43.8% | 44.9% |
| Net Loss | $(0.27) million | $(11.31) million | $(2.82) million |
| Operating Cash Flow | $(1.47) million | $0.05 million | $(0.66) million |
| Cash & Equivalents (End of Period) | $7.84 million | $7.55 million | $11.52 million |
| Total Assets | $25.88 million | $24.42 million | N/A |
| Total Liabilities | $1.73 million | $3.38 million | N/A |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 18.4% to $15.86 million. This was primarily driven by a $6.9 million decrease in patented drug sales, which peaked in 2023 due to COVID-19 demand. The decline was partially offset by a $1.3 million increase in medical training services and a $1.9 million increase in patient management services.
- Profitability Improvement: Net loss narrowed significantly to $0.27 million from $11.31 million in 2023. The 2023 loss included non-recurring impairments of goodwill ($5.62 million) and intangible assets ($0.54 million) related to the West Angel acquisition, as well as a $1.72 million loss from the forced demolition of a Beijing property.
- Margin Expansion: Gross margin improved to 56.2% from 43.8%, driven by a shift in service mix toward higher-margin consulting and academic support services.
- Capital Raising: In 2024, the Company raised approximately $3.84 million through a registered direct offering and a private placement (including cashless warrant exercises).
Guidance, Outlook, and Risks
Outlook: Management intends to use cash reserves to strengthen brand awareness, expand medical course content, grow the professional user community, and develop new teaching platforms. No specific financial guidance was provided in the filing.
Material Risks:
- VIE Structure: The Company relies on contractual arrangements to control PRC operating entities. If PRC authorities deem these arrangements invalid, the Company could lose control of its primary assets and operations.
- Regulatory Environment: Significant uncertainty exists regarding PRC laws on overseas listings (CSRC filing requirements), data security (Cybersecurity Review Measures), and the education/healthcare sectors. Changes could restrict operations or require restructuring.
- Internal Controls: The Company identified material weaknesses in internal control over financial reporting, including a lack of monitoring mechanisms and insufficient US GAAP expertise. Remediation efforts are underway.
- Customer Concentration: In 2024, two customers accounted for approximately 29.2% of total revenue. Loss of major customers could materially impact results.
- PCAOB Inspection: While the PCAOB has secured access to inspect auditors in China, continued access is subject to uncertainty, which could impact listing status under the HFCA Act.
Investor Verification Checklist
- VIE Validity: Verify the current status of the Variable Interest Entity agreements and any recent PRC regulatory actions affecting similar structures.
- Drug Sales Sustainability: Assess the long-term demand for the patented drug segment, which drove 2023 revenue but normalized in 2024.
- Internal Control Remediation: Review the progress of remediation for the identified material weaknesses in internal controls over financial reporting.
- Liquidity Runway: Confirm that the $7.84 million cash balance is sufficient to fund operations given the negative operating cash flow of $1.47 million in 2024.
- Customer Concentration: Investigate the stability of contracts with the top two customers representing nearly 30% of revenue.